Πέμπτη 19 Ιανουαρίου 2012
Novartis tops patient groups' "reputation table"
Novartis has the best corporate reputation out of 30 companies within the pharmaceutical industry, according to a survey of 500 large and influential patient groups worldwide.
The Swiss major came top in four of the six indicators on which the survey, conducted by PatientView, asked the patient groups to rate companies. Specifically, they considered Novartis to be the best of the 30 at: - having an effective patient-centred strategy; - the quality of the information for patients which it provides; - its record on patient safety; and - the usefulness of its products to patients.
Gilead was judged best of the 30 firms for both the other two indicators - its record on transparency with external stakeholders and whether it acts with integrity - for which Novartis came second and third, respectively.
The Swiss major came top in four of the six indicators on which the survey, conducted by PatientView, asked the patient groups to rate companies. Specifically, they considered Novartis to be the best of the 30 at: - having an effective patient-centred strategy; - the quality of the information for patients which it provides; - its record on patient safety; and - the usefulness of its products to patients.
Gilead was judged best of the 30 firms for both the other two indicators - its record on transparency with external stakeholders and whether it acts with integrity - for which Novartis came second and third, respectively.
Top 11 Trends for 2012 in Healthcare Data, According to Industry Experts
Hospitals and healthcare organizations will need more than a couple of aspirin to ready themselves for 2012. Industry experts representing healthcare law, privacy, security, regulatory and data breach were asked to forecast healthcare data trends for 2012. The overall forecast? Protecting patients' protected health information (PHI) should be viewed as a patient safety issue. If the right actions are not taken, experts predict healthcare data breach will reach epidemic proportions this year.
2011 was the year when most physicians had mobile devices; when healthcare became one of the most-breached industries; and the Department of Health and Human Services Office for Civil Rights (OCR) cracked the whip with investigations and multi-million-dollar fines for organizations that didn't meet their patient privacy obligations.
2011 was the year when most physicians had mobile devices; when healthcare became one of the most-breached industries; and the Department of Health and Human Services Office for Civil Rights (OCR) cracked the whip with investigations and multi-million-dollar fines for organizations that didn't meet their patient privacy obligations.
Amgen Announces Plans To Make Generics With Watson Pharmaceuticals
Amgen is planning to team up with Watson Pharmaceuticals to develop generic versions of some popular drugs. The partnership will develop and sell lower-priced copycat versions of several biologic cancer drugs, which are usually called biosimilars. Amgen’s deal with Watson will not copy any Amgen drugs.
Amgen executives indicated earlier this year that a biosimilar business might make some sense for the company. Scott Foraker, head of biosimilars at Amgen, said in an interview that Amgen has always said biosimilars have a role as long as the patent protection on the innovative drug was respected. Mr. Foraker said, “We have purposely been keeping it under wraps as long as we could.”
Amgen executives indicated earlier this year that a biosimilar business might make some sense for the company. Scott Foraker, head of biosimilars at Amgen, said in an interview that Amgen has always said biosimilars have a role as long as the patent protection on the innovative drug was respected. Mr. Foraker said, “We have purposely been keeping it under wraps as long as we could.”
Smart Pill Contains Microchip to Monitor Patients’ Medication
REDWOOD CITY, Calif.--(BUSINESS WIRE)--UK community pharmacy chain Lloydspharmacy and US company Proteus Biomedical, Inc., a pioneer in digital health, have today announced an exclusive strategic collaboration to commercialize and launch Helius™, a digital health product focused on consumers and family caregivers.
Helius has been designed to provide assurance and peace of mind to individuals struggling with complex medication regimens and health issues, and to connect these individuals to the family, friends and professionals caring for them. As part of the agreement with Proteus, Lloydspharmacy will launch Helius in the UK and sell the system through selected pharmacies. Helius will be paid for by consumers and their families.
Sanofi to introduce iBGStar blood glucose meter in UK
An upgraded version of the successful BGStar device, the new meter has already been introduced in a number of European markets and will be the first device of its kind to connect to the iPhone and iPod Touch, reports Chemist and Druggist.
When connected to the Apple devices, stored data will be automatically transferred across for viewing via a free diabetes manager app, which will be made available through iTunes.
This application tracks a variety of diabetes information, allowing users to easily identify trends and variations with or without the assistance of healthcare professionals.
Sanofi's iBGStar will be fully compatible with BGStar blood glucose test strips and lancets, which are currently available via NHS prescription.
This follows on from the introduction of iBGStar in Italy, Switzerland and the Netherlands in the latter half of 2011.
Major Pharmaceutical Firms Showing Appetite for Larger Acquisitions
NEW YORK, NY, Jan 18, 2012 (MARKETWIRE via COMTEX) -- According to a recent article from The Wall Street Journal, analysts are turning "bullish" on the pharmaceutical industry once again. There are 3,000 drugs in development in the U.S. today compared to about 2,000 a decade ago. Many of these medicines target unmet needs like Alzheimer's and stroke, where the advances in care can be substantial. Almost a third target forms of cancer, some of which are poorly treated today, the Journal reports.
2012 is expected to be a big year for M&A activity in the Pharmaceuticals industry. According to a recent article from FiercePharma drugmaker CEOs have been describing their appetites for deals in recent weeks. CEOs from large Pharmaceutical firms such as Pfizer, Roche, Sanofi and Bristol-Myers Squibb have expressed interest in deals for as much as $3B this year.
The Pharma Letter recently reported that while there were few multi-billion dollar deals last year, 2011 turned into a "bumper year" for the number of merger and acquisition deals for pharmaceutical, biotechnology and generic drugmakers with a total of 129 M&A announcements recorded.
Pharmaceutical spam: Medical disinformation on the internet
Spam advertising of pharmaceutical products is leading patients to seek out information about prescription drugs online, according to a report to be published in the International Journal Business and Systems Research. If those drugs are not available to the internet user through their physician there is a risk that they may obtain such products via illicit means.
The direct advertising of pharmaceutical products to patients is outlawed in several countries, but spam marketing is all-pervasive and wholly ignores national and international laws. It exists because a sale to even a tiny percentage of the hundreds of millions of people targeted every single day with product offers nets the spammers a profit. Now, Sanjoy Ghose and Vikas Lachhwani of the University of Wisconsin-Milwaukee, have investigated how exposure to spam offering prescription pharmaceuticals motivates individuals to seek additional information on the internet.
The direct advertising of pharmaceutical products to patients is outlawed in several countries, but spam marketing is all-pervasive and wholly ignores national and international laws. It exists because a sale to even a tiny percentage of the hundreds of millions of people targeted every single day with product offers nets the spammers a profit. Now, Sanjoy Ghose and Vikas Lachhwani of the University of Wisconsin-Milwaukee, have investigated how exposure to spam offering prescription pharmaceuticals motivates individuals to seek additional information on the internet.
Εγγραφή σε:
Αναρτήσεις (Atom)